Company Overview and News
Houston, April 19, 2018 (GLOBE NEWSWIRE) -- Shell Midstream Partners, L.P. (NYSE: SHLX) will host a conference call on Thursday, May 3rd at 8:30am CT to discuss 2018 first-quarter financial results. Shell Midstream Partners’ participants will be Kevin Nichols, president and chief executive officer and Shawn Carsten, chief financial officer.
Investors occasionally ask us what distribution coverage looks like for MLPs. While it may seem straightforward, it is somewhat of a loaded question. Distribution coverage (or coverage ratio) compares distributable cash flow (DCF) generated in a period to the total cash distributions paid for that period. Investors look at distribution coverage to better understand an MLP's ability to pay distributions from the cash generated by its operations.
Navios Maritime Midstream Partners (NAP) is an MLP involved in the marine transportation of fuel including crude oil, refined products, and NGLs (natural gas liquids). In the week ending April 6, 2018, Navios Maritime Midstream Partners had the top MLP loss for the second consecutive week. Navios Maritime Midstream Partners fell 10.9% last week. Overall, the partnership has lost ~59% in the past two weeks.
Broker top-ten net-gain "Safer" dividend energy March stocks (per 1yr. targets) were HEP, DCP, EP, EQGP, GLOP, GPP, VLP, EQM, TEGP, & led by SHLX with 21.6%-55.45% gains.
Interstate pipeline MLPs continued to be among the worst performers in the week ending March 23 due to downward price revisions from various Wall Street analysts. Dominion Midstream Energy Partners (DM) and Spectra Energy Partners (SEP) were among the top three MLPs losses last week. They fell 24.8% and 10.8% last week.
From 2/1-3/5/18, Fredrik Arnold dividend "followers" discussed 49 equities and funds in their messages and comments. Some comments were bad news, so bad rogues mixed into a FollowerFavorite/Rogue (FoFa/Ro) list.
Houston, March 19, 2018 (GLOBE NEWSWIRE) -- Shell Midstream Partners, L.P. (NYSE: SHLX) has announced the successful completion of the Zydeco integrity project. The pipeline is expected to resume normal operations this week with financial impact materially in line with prior guidance. “We took pro-active steps to ensure the integrity and reliability of the system well into the future. It was the right thing to do to meet the needs of our customers, investors, and the communities in which we operate” said John Hollowell, CEO Shell Midstream Partners.
In the week ending March 2, 2018, Legacy Reserves (LGCY), an upstream MLP involved in crude, natural gas, and NGLs (natural gas liquids) production, was the top MLP gainer for the second consecutive week. Legacy Reserves shares jumped 20.9% last week. The rally last week could be due to gains in natural gas prices and strong positive momentum following the fourth quarter earnings announcement. Overall, Legacy Reserves has risen 74.
CIBC Atlantic Trust Private Wealth Management and Alps Advisors added a major position in Andeavor Logistics (ANDX) during the recent quarter. They bought 1.44 million and 1.43 million shares, respectively. On the other hand, Bank of America Merrill Lynch and Goldman Sachs & Company were the biggest sellers. They sold 0.68 million shares and 0.65 million shares of ANDX during the fourth quarter, respectively.
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2018 (February 26, 2018) Shell Midstream Partners, L.P. (Exact name of registrant as specified in its charter) Delaware 001-36710 46-5223743 (State or other jurisdiction of incorporation) (Commission File Number) (I.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...
as of ET